Abstract
Cancer Biotherapy & RadiopharmaceuticalsVol. 36, No. 7 RetractionsOpen AccessRetraction of: Targeted Regulation of miR-26a on PTEN to Affect Proliferation and Apoptosis of Prostate Cancer Cells (doi: 10.1089/cbr.2018.2664)Published Online:6 Sep 2021https://doi.org/10.1089/cbr.2018.2664.retractAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Cancer Biotherapy and Radiopharmaceuticals officially retracts the paper entitled, “Targeted Regulation of miR-26a on PTEN to Affect Proliferation and Apoptosis of Prostate Cancer Cells” by Weilu Li, Yongjun Jiang, Xia Wu, and Fucun Yang (Cancer Biother Radiopharm 2019;34(7):480-485; doi: 10.1089/cbr.2018.2664) due to the discovery that the paper was submitted from a paper mill which is a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing.The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves and does not tolerate any violations of scientific misconduct.FiguresReferencesRelatedDetails Volume 36Issue 7Sep 2021 InformationCopyright 2021, Mary Ann Liebert, Inc., publishersTo cite this article:Retraction of: Targeted Regulation of miR-26a on PTEN to Affect Proliferation and Apoptosis of Prostate Cancer Cells (doi: 10.1089/cbr.2018.2664).Cancer Biotherapy and Radiopharmaceuticals.Sep 2021.615-615.http://doi.org/10.1089/cbr.2018.2664.retractcreative commons licensePublished in Volume: 36 Issue 7: September 6, 2021Online Ahead of Print:August 6, 2021PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
